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OBJECTIVE: We sought to evaluate the neurohormonal activity in heart transplant recipients and compare it with that in heart 
failure patients and healthy subjects during rest and just after a 6-minute walking test. 
INTRODUCTION: Despite the improvements in quality of life and survival provided by heart transplantation, the neurohormonal 
profile is poorly described. 
METHODS: Twenty heart transplantation (18 men, 49±11 years and 8.5±3.3 years after transplantation), 11 heart failure (8 men, 
43±10 years), and 7 healthy subjects (5 men 39±8 years) were included in this study. Blood samples were collected immediately 
before and during the last minute of the exercise. 
RESULTS: During rest, patients’ norepinephrine plasma level (659±225 pg/mL) was higher in heart transplant recipients (463±167 
pg/mL) and heathy subjects (512±132), p<0.05. Heart transplant recipient’s norepinephrine plasma level was not different than that 
of healthy subjects. Just after the 6-minute walking test, the heart transplant recipient’s norepinephrine plasma level (1248±692 
pg/mL) was not different from that of heart failure patients (1174±653 pg/mL). Both these groups had a higher level than healthy 
subjects had (545±95 pg/mL), p<0.05. 
CONCLUSION: Neurohormonal activity remains increased after the 6-minute walking test after heart transplantation.
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INTRODUCTION
Heart failure is considered the last stage of heart disease and 
a significant cause of worldwide mortality and morbidity.1,2,3 
The end-stage of heart failure, which is marked by a lack 
of response to medical treatment, disabling symptoms, and 
repeated hospital stays, is associated with high morbidity and 
mortality.4 Heart transplantation is an acceptable gold standard 
treatment for select patients in the terminal stages.5
The exacerbated neurohormonal activity plays an 
important role in disease progression and prognosis in heart 
failure.6,7,8,9 This neurohormonal axis has become one of the 
biggest targets in heart failure interventions.10,11,12,13,14,15 It is 
well known that beta-blockers provide survival improvement 
and, because of this, have become one of the main drugs for 
treating heart failure.16
Despite the significant improvement in quality of 
life and survival provided by heart transplantation, the 
neurohormonal profile is not restored to normal values.6 The 
mechanisms involved and the neurohormonal profile after 
heart transplantation have been poorly described, especially 
during the 6-minute walking tests that could represent the 
effort relative to daily activities.17
The aim of this study was to evaluate the neurohormonal 
activity in heart transplant recipients and compare it with 
that in heart failure and healthy subjects during rest and just 
after the 6-minute walking test.588
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MATERIALS AND METHODS
Study population
A total of 20 sedentary heart transplant recipients (18 
men, 49±11 years), 11 sedentary heart failure patients 
(8 men, 43±10 years), and 7 sedentary healthy subjects 
(5 men 39±8 years) were included in this study. Patient 
characteristics are shown in Table 1. All heart transplant 
recipients were in a clinically stable condition 8.5±3.3 
years after transplantation. Endomyocardial biopsy did 
not show any evidence of tissue rejection during the entire 
study. Heart transplant recipients and heart failure patients 
with atrial fibrillation, a pacemaker, and noncardiovascular 
functional limitations like osteoarthritis were excluded from 
this study. Heart failure patients whose drug therapy was not 
optimized were also excluded from this study. Optimization 
was considered 50 mg/day or more of carvedilol for at least 
3 months.18 Healthy subjects did not have any risk factors 
for cardiovascular disease or noncardiovascular functional 
limitations.
This protocol was approved by the Ethics Committee of 
Table 1 - Patient characteristics.
Number of patients (%), dose (mg/day)
Etiology: Heart Failure Heart Transplantation
   Ischemic  35% 16%
   Nonischemic 65% 84%
NYHA functional class:
   I  60% ---
   II  40% ---
Left ventricle ejection fraction 25±11% ---
Current medications:
Diuretics 
   Furosemide 60%, 52±30mg/day 25%, 33±11 mg/day
   Hydrochlorothiazide 50%, 43±24md/day 25%, 26±2md/day
Angiotensin-converting enzyme inhibitors 
   Enalapril 70%, 38±6mg/day 50%16±5mg/day
   Captopril 15%, 93±37mg/day ---
Losartan 15%, 75±29mg/day 10%, 50±0mg/day
Carvedilol 100%, 61±30mg/day ---
Spironolactone  35%, 25±0mg/day ---
Digoxin 45%, 0.25±0mg/day ---
Isosorbide 5-mononitrate
Immunosuppressive drugs 
   Corticosteroids (prednisone)
   Antiproliferative agents
       Azathioprine 
       Mycophenolate mofetil
   TOR inhibitors
       Tacrolimus
       Sirolimus
   Calcineurin inhibitors (Cyclosporine)
Calcium channel blocker (Diltiazem)
Hydralazine
Clonidim
Atorvastatin
Ezetimibe
15%, 56±35mg/day
-----
-----
-----
-----
-----
-----
-----
-----
-----
-----
-----
---
57%, 4.5±1mg/day
21%, 75±35mg/day
71%, 744±488mg/day
7%,    8±0mg/day
7%,    2±0mg/day
71%,  161±57mg/day
78%   78±54mg/day
14%   25±0mg/day
28%   0.1±0.1mg/day
7%    20±0mg/day
7%   10±0mg/day589
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the Heart Institute, InCor HCFMUSP. All patients provided 
informed consent prior to participation.
Six-minute walking test and blood norepinephrine
All patients were asked to refrain from both strenuous 
physical activity and the consumption of any stimulants 
(eg, coffee, tobacco, alcohol) 24 hours prior to the 6CWT. 
The patients’ last meal was ingested at least 2 hours before 
the start of the test. Before starting the 6CWT and blood 
sample collection, the patients rested for 15 minutes on a 
chair. The 6CWT using the Borg scale was performed on a 
treadmill with zero inclination and patient-controlled speed 
in a temperature-controlled room (21–23°C) in the afternoon 
(between 13:00 hours and 15:00 hours). All patients were 
advised to keep walking during the test at a pace between 
“relatively easy and slightly tiring” (between 11 and 13 on 
the Borg scale). The distance walked was recorded by the 
treadmill microprocessor (Series 2000, Marquette Electronics, 
Milwaukee, WI, USA). Encouragement was standardized with 
phrases like “if you can walk faster, increase the speed”, “you 
are doing very well,” and “if it is tiring, you can reduce the 
speed.” Blood pressure was measured at rest and at the sixth 
minute by the auscultation method. The electrocardiography 
(Max 1, Marquette Electronics), ventilatory and gas exchange 
variables were continuously evaluated breath-by-breath by 
a computerized system (Vmax 229 model, SensorMedics, 
Yorba Linda, CA, USA) during the entire test but only 
collected at rest (stand position) and just after the 6-minute 
walking test. The 6-minute walking test has been shown to 
reflect submaximal effort in heart failure patients19 and to 
reproduce the daily activities.20 Blood samples were collected 
immediately before the 6-minute walking test with patients 
in the upright position and just after the exercise by the 
antecubital vein. The norepinephrine assay was performed as 
previously reported.21 
Current medication intake
All heart failure patients were receiving carvedilol 
associated with an ACE inhibitor or losartan. Medication 
profile is shown in Table 1. Patients took carvedilol, 
angiotensin-converting enzyme inhibitors, losartan, and 
Isosorbide 5-mononitrate twice per day, one half of the 
daily dose in the morning (9:00 a.m.) and the other half at 
night (9:00  p.m.). Diuretics, digoxin, and spironolactone 
were taken in the morning (9:00 a.m.). All heart transplant 
recipients were receiving immunosuppressive therapy two 
times per day, one half of the daily dose in the morning and 
the other half at night. Antihypertensive drugs were normally 
taken in the morning.
Statistical analysis
The descriptive analysis is presented as the mean and 
standard deviation. To compare the norepinephrine levels 
between the 3 groups, we used the ANOVA with the post-
hoc Tukey test.
Data were analyzed using the Statistical Package for 
Social Sciences for Windows, 11.5 (SPSS Inc, Chicago, IL). 
Statistical significance was set at p < 0.05.
RESULTS
During rest, norepinephrine plasma level was higher 
in heart transplant recipients and healthy subjects. Heart 
transplant recipients’ norepinephrine plasma level was not 
different than that of healthy subjects. Just after the 6-minute 
walking test, heart transplant recipients’ norepinephrine 
plasma level was not different than that of heart failure 
patients and both these groups had a higher level of 
norepinephrine than did healthy subjects. Exercise capacity 
and hemodynamic data are listed in table 2. 
DISCUSSION
The main finding of this study is that norepinephrine 
remained increased just after the 6-minute walking test in 
heart transplant recipients. This is the first report of the 
norepinephrine profile during a 6-minute walking test in 
heart transplant recipients.
It is known that daily activities are not performed at 
maximal effort. That it’s why we studied the neurohormonal 
profile in a 6-minute walking test. This way, we could access 
the norepinephrine in a more functional status.
The intensity of the 6-minute walking test, between 
11 and 13 on the Borg scale, was similar for all groups, 
which are expected to spend about the same metabolic 
or VO2, regardless of physical status. The same distance 
covered by the groups could be explained by their sedentary 
characteristic. Moreover, they were all clinically stable 
outpatients with optimized medication.22
Pérez-Villa et al6 studied the neurohormonal profile 
of 37 heart failure patients on the waiting list for heart 
transplantation before and 1, 4, 9, and 12 months after 
heart transplantation. The authors concluded that the 
neurohormonal activation did not normalize after heart 
transplantation. In this study, plasma norepinephrine 
level was only recorded before and 1 month after heart 
transplantation, showing a tendency to decrease. In 
our study, the heart failure group had a higher level of 
resting norepinephrine compared with heart transplant 
recipients and healthy subjects. The norepinephrine level 590
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of the heart transplant recipients did not differ from that 
of healthy subjects, probably by the partial reinnervation 
that occurred during the 8.5 years. Heart function after 
transplantation depends on the circulating norepinephrines. 
The progressive heart reinnervation through the years 
could have progressively decreased the necessity for 
norepinephrine plasma levels in heart transplant recipients.
The study by Ferretti et al8 evaluated the neurohormonal 
profile of 17 heart transplant recipients and 9 healthy 
subjects at rest and at maximal exercise. The resting 
norepinephrine plasma level was higher in heart transplant 
recipients than in healthy subjects. In our study, the 
resting norepinephrine did not differ between heart 
transplant recipients and healthy subjects. The time of 
heart transplantation, ie, different stages of reinnervation, 
between our heart transplant recipients and the ones in the 
study by Ferretti et al was different (8.5 versus 3.4 years). 
This difference could explain these divergent results. During 
exercise, the norepinephrine plasma level was also higher 
in heart transplant recipients compared with that in healthy 
subjects. This is in accordance with our results, despite the 
fact that our heart transplant recipients had performed a 
6-minute walking test.
Study limitation
This study was limited by the study design (cross-
sectional), small study population, and the use of a single 
method of neurohormonal evaluation.
CONCLUSION
The norepinephrine remained increased just after the 
6-minute walking test in heart transplant recipients. The 
consequences of these data should be better investigated in 
heart transplant recipients.
Table 2 - Differences between patients.
Variable NL (n=7) HF (n=11) HT (n=20)
Resting heart rate (bpm) 80±10 72±5 104±14*‡
6WT Heart rate (bpm) 97±15 95±12 122±21*‡
Resting Norepinephrine (pg/mL) 512±132 659±225*† 463±167
6WT Norepinephrine (pg/mL) 545±95 1174±653* 1248±692*
Resting SBP (mm Hg) 121±12 111±12 140±24*‡
6WT SBP (mm Hg) 142±15‡ 123±19 152±24‡
Resting DBP (mm Hg) 69±11 61±12 83±16*‡
6WT DBP (mm Hg) 74±9‡ 61±10 82±16‡
6WT VO2 (mLO2/L/min) 12.6±4.1 12.3±4.8 14.1±2.2
VE/VCO2 slope 20±3 25±5* 33±6*‡
Distance (meters) 386±96 322±48 354±64
HT= Heart transHT= Heart transplantation; HF= Heart failure; NL= Normals; 6WT= Six-minute walking test; SBP= Systolic blood pressure; DBP= Dia-
stolic blood pressure; VO2= Oxygen Consumption; *p<0.05 different to NL; †p<0.05 different to HT; ‡p<0.05 different to HF.
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